CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This study is a single arm, phase II trial, of 45 patients with locally advanced pancreatic
ductal adenocarcinoma. The efficacy of the novel drug and mitochondrial inhibitor, CPI-613,
in conjunction with standard-of-care FOLFRINOX, as a first-line therapy will be evaluated.
Pre-treatment, diagnostic biopsy tissue will be collected when available, and clinical data
will be evaluated to determine if the combination results in improved overall survival
compared to historical experience.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University